MedTrace Logo

Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis

NCT04074629 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2022-12-07

No results posted yet for this study

Summary

Multiple Sclerosis (MS) is the most common chronic neurological disease affecting young adults, with onset usually at the age 20-40 years. The disease is characterized by two main phenotypes: Relapse-Remitting MS (RR-MS) and Primary Progressive MS (PP-MS). RR-MS is the most common type of disease, for long-term management of the disease patients are treated with immunomodulatory drugs (IMD) which reduce disease activity. Response to therapy varies among patients. Presently there are no biomarkers available for diagnosis and routine follow-up of MS. Many MS patients suffer from unexpected relapsing episodes that influence dramatically their mental and physical conditions, with high stress levels, tremors, motoric disabilities, blindness and more. Therefore, early target treatment in relapse episodes is crucial, yet sufficient tools for predicting and identifying early symptoms of an upcoming relapse episode are not available. The investigators have most recently shown that breath VOCs can be used to classify among MS and non-MS patients. The major aims of the current proposal is to study the plausibility of skin based VOCs as biomarkers for MS diagnosis and To Identify and characterize skin-based VOCs as biomarkers of the clinical relapse and disease activity.

Conditions

Interventions

DIAGNOSTIC_TEST

Diagnosis, skin volatile organic compounds (VOCs)

The skin related VOCs will be collected by "off-line" method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • Carmel Medical Center

    lead OTHER

Principal Investigators

  • Ariel Miller · Multiple Sclerosis Clinc, Carmel Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-16
Primary Completion
2022-05-23
Completion
2022-08-02

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04074629 on ClinicalTrials.gov